Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women

Travis Anderson, Sandra J. Shultz, Nancy Williams, Ellen Casey, Zachary Kincaid, Jay L. Lieberman, Laurie Wideman

Research output: Contribution to journalArticle

Abstract

Evidence suggests menstrual cycle variation in the hormone relaxin may have an impact on ligament integrity and may be associated with risk of anterior cruciate ligament injury in physically active women. However, studies to date have only detected relaxin in a small number of participants, possibly due to inter-individual variability, frequency of sample collection, or analytical techniques. Therefore, the purpose of this study was to analyze serial serum samples in moderately active, eumenorrheic women to identify the proportion of women with detectable relaxin concentrations. Secondary analyses were conducted on two independent data sets. Data Set I (DSI; N = 66) participants provided samples for 6 days of menses and 8–10 days of the luteal phase. Data Set II (DSII; N = 15) participants provided samples every 2–3 days for a full menstrual cycle. Samples were analyzed via a relaxin-2 specific ELISA assay. Limit of detection (LOD) was calculated from the empirical assay data. LOD was calculated as 3.57 pg·ml−1. Relaxin concentrations exceeded the LOD in 90.91% (DSI) and 93.33% (DSII) of participants on at least 1 day of sampling. Actual peak values ranged from 0.0 pg·ml−1 to 118.0 pg·ml−1. Relaxin was detectable in a higher proportion of young women representing a broad range of physical activity levels when sampled more frequently. Future studies investigating relaxin should consider sampling on more than 1 day to accurately capture values among normal menstruating women.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalWomen in Sport and Physical Activity Journal
Volume27
Issue number1
DOIs
StatePublished - Apr 1 2019

Fingerprint

Relaxin
Limit of Detection
Menstrual Cycle
integrity
Values
Menstruation
Luteal Phase
Ligaments
Reference Values
Enzyme-Linked Immunosorbent Assay
Hormones
Exercise
evidence
Serum

All Science Journal Classification (ASJC) codes

  • Education
  • Gender Studies
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Anderson, Travis ; Shultz, Sandra J. ; Williams, Nancy ; Casey, Ellen ; Kincaid, Zachary ; Lieberman, Jay L. ; Wideman, Laurie. / Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women. In: Women in Sport and Physical Activity Journal. 2019 ; Vol. 27, No. 1. pp. 30-36.
@article{938b54799dcd46268dd8c0bc2136dfcd,
title = "Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women",
abstract = "Evidence suggests menstrual cycle variation in the hormone relaxin may have an impact on ligament integrity and may be associated with risk of anterior cruciate ligament injury in physically active women. However, studies to date have only detected relaxin in a small number of participants, possibly due to inter-individual variability, frequency of sample collection, or analytical techniques. Therefore, the purpose of this study was to analyze serial serum samples in moderately active, eumenorrheic women to identify the proportion of women with detectable relaxin concentrations. Secondary analyses were conducted on two independent data sets. Data Set I (DSI; N = 66) participants provided samples for 6 days of menses and 8–10 days of the luteal phase. Data Set II (DSII; N = 15) participants provided samples every 2–3 days for a full menstrual cycle. Samples were analyzed via a relaxin-2 specific ELISA assay. Limit of detection (LOD) was calculated from the empirical assay data. LOD was calculated as 3.57 pg·ml−1. Relaxin concentrations exceeded the LOD in 90.91{\%} (DSI) and 93.33{\%} (DSII) of participants on at least 1 day of sampling. Actual peak values ranged from 0.0 pg·ml−1 to 118.0 pg·ml−1. Relaxin was detectable in a higher proportion of young women representing a broad range of physical activity levels when sampled more frequently. Future studies investigating relaxin should consider sampling on more than 1 day to accurately capture values among normal menstruating women.",
author = "Travis Anderson and Shultz, {Sandra J.} and Nancy Williams and Ellen Casey and Zachary Kincaid and Lieberman, {Jay L.} and Laurie Wideman",
year = "2019",
month = "4",
day = "1",
doi = "10.1123/wspaj.2018-0014",
language = "English (US)",
volume = "27",
pages = "30--36",
journal = "Women in Sport and Physical Activity Journal",
issn = "1063-6161",
publisher = "Human Kinetics Publishers Inc.",
number = "1",

}

Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women. / Anderson, Travis; Shultz, Sandra J.; Williams, Nancy; Casey, Ellen; Kincaid, Zachary; Lieberman, Jay L.; Wideman, Laurie.

In: Women in Sport and Physical Activity Journal, Vol. 27, No. 1, 01.04.2019, p. 30-36.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women

AU - Anderson, Travis

AU - Shultz, Sandra J.

AU - Williams, Nancy

AU - Casey, Ellen

AU - Kincaid, Zachary

AU - Lieberman, Jay L.

AU - Wideman, Laurie

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Evidence suggests menstrual cycle variation in the hormone relaxin may have an impact on ligament integrity and may be associated with risk of anterior cruciate ligament injury in physically active women. However, studies to date have only detected relaxin in a small number of participants, possibly due to inter-individual variability, frequency of sample collection, or analytical techniques. Therefore, the purpose of this study was to analyze serial serum samples in moderately active, eumenorrheic women to identify the proportion of women with detectable relaxin concentrations. Secondary analyses were conducted on two independent data sets. Data Set I (DSI; N = 66) participants provided samples for 6 days of menses and 8–10 days of the luteal phase. Data Set II (DSII; N = 15) participants provided samples every 2–3 days for a full menstrual cycle. Samples were analyzed via a relaxin-2 specific ELISA assay. Limit of detection (LOD) was calculated from the empirical assay data. LOD was calculated as 3.57 pg·ml−1. Relaxin concentrations exceeded the LOD in 90.91% (DSI) and 93.33% (DSII) of participants on at least 1 day of sampling. Actual peak values ranged from 0.0 pg·ml−1 to 118.0 pg·ml−1. Relaxin was detectable in a higher proportion of young women representing a broad range of physical activity levels when sampled more frequently. Future studies investigating relaxin should consider sampling on more than 1 day to accurately capture values among normal menstruating women.

AB - Evidence suggests menstrual cycle variation in the hormone relaxin may have an impact on ligament integrity and may be associated with risk of anterior cruciate ligament injury in physically active women. However, studies to date have only detected relaxin in a small number of participants, possibly due to inter-individual variability, frequency of sample collection, or analytical techniques. Therefore, the purpose of this study was to analyze serial serum samples in moderately active, eumenorrheic women to identify the proportion of women with detectable relaxin concentrations. Secondary analyses were conducted on two independent data sets. Data Set I (DSI; N = 66) participants provided samples for 6 days of menses and 8–10 days of the luteal phase. Data Set II (DSII; N = 15) participants provided samples every 2–3 days for a full menstrual cycle. Samples were analyzed via a relaxin-2 specific ELISA assay. Limit of detection (LOD) was calculated from the empirical assay data. LOD was calculated as 3.57 pg·ml−1. Relaxin concentrations exceeded the LOD in 90.91% (DSI) and 93.33% (DSII) of participants on at least 1 day of sampling. Actual peak values ranged from 0.0 pg·ml−1 to 118.0 pg·ml−1. Relaxin was detectable in a higher proportion of young women representing a broad range of physical activity levels when sampled more frequently. Future studies investigating relaxin should consider sampling on more than 1 day to accurately capture values among normal menstruating women.

UR - http://www.scopus.com/inward/record.url?scp=85068027630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068027630&partnerID=8YFLogxK

U2 - 10.1123/wspaj.2018-0014

DO - 10.1123/wspaj.2018-0014

M3 - Article

VL - 27

SP - 30

EP - 36

JO - Women in Sport and Physical Activity Journal

JF - Women in Sport and Physical Activity Journal

SN - 1063-6161

IS - 1

ER -